NCT03623854View on ClinicalTrials.gov

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

April 3, 2019

Primary Completion Date

September 28, 2023

Study Completion Date

September 28, 2023

Conditions

ChordomaLocally Advanced ChordomaMetastatic ChordomaUnresectable Chordoma

Interventions

BIOLOGICAL

Nivolumab

Given IV

BIOLOGICAL

Relatlimab

Given via infusion

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT03623854 - Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | Biotech Hunter | Biotech Hunter